Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model

Neuropilin-1/-2 (+33 NRPs), VEGF-A 165 co-receptors , are over-expressed during cancer progression. Thus, NRPs targeted drug development is challenged using a multistep in silico/in vitro screening procedure. The first fully non-peptidic VEGF-A 165 /NRPs protein–protein interaction antagonist (IC 50 = 34 μM) without effect on pro-angiogenic kinases has been identified (compound-1). This hit showed breast cancer cells anti-proliferative activity (IC 50 = 0.60 μM). Compound-1 treated NOG-xenografted mice significantly exerted tumor growth inhibition, which is correlated with Ki-67 low expression and apoptosis. Furthermore, CD31 + /CD34 + vessels are reduced in accordance with HUVEC-tube formation inhibition (IC 50 = 0.20 μM). Taking together, compound-1 is the first fully organic inhibitor targeting NRPs.